Mexican Faculty of Medicine, 27840La Salle University, Mexico City, Mexico.
Clinical Neurodegenerative Research Unit, 61614National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
J Geriatr Psychiatry Neurol. 2021 Jan;34(1):60-65. doi: 10.1177/0891988720901787. Epub 2020 Feb 6.
To assess the frequency of somatization and its association with motor, nonmotor symptoms, and quality of life in persons with Parkinson disease (PD).
A cross-sectional case-control study was carried out. Assessments included the List of 90 Symptoms somatic factor (SCL-90-R SOM), Movement Disorder Society Unified Parkinson's Ratings Scale (MDS-UPDRS), Non-Motor Symptom Scale (NMSS), Montreal Cognitive Assessment (MoCA), and Parkinson Questionnaire-8 (PDQ-8).
A total 93 persons with PD and 93 controls were included. Somatization within the PD group was 2 times more frequent compared to the control group (43% vs 21.5%, = .003). Persons with PD had higher NMSS total scores (48.6 ± 42.6 vs 28.3 ± 30.4, = .001). Patients with PD with somatization had worst MDS-UPDRS, NMSS, MoCA, and PDQ-8 (all < .05).
Somatization is more frequent in persons with PD compared to healthy controls. Somatization in PD is associated with nonmotor symptoms and worst quality of life.
评估躯体化的频率及其与帕金森病（PD）患者的运动和非运动症状及生活质量的关系。
进行了一项横断面病例对照研究。评估包括症状清单 90 项躯体化因子（SCL-90-R SOM）、运动障碍协会统一帕金森病评定量表（MDS-UPDRS）、非运动症状量表（NMSS）、蒙特利尔认知评估量表（MoCA）和帕金森病问卷-8 （PDQ-8）。
共纳入 93 例 PD 患者和 93 名对照者。与对照组相比，PD 组躯体化的发生率高 2 倍（43%比 21.5%，P =.003）。PD 患者 NMSS 总分较高（48.6±42.6 比 28.3±30.4，P =.001）。有躯体化的 PD 患者的 MDS-UPDRS、NMSS、MoCA 和 PDQ-8 评分最差（均 P<.05）。
与健康对照组相比，PD 患者躯体化更为常见。PD 中的躯体化与非运动症状和最差的生活质量有关。
